Friday, July 10, 2026

pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA

Olema Pharmaceuticals

Olema Pharmaceuticals is a pharma organization headquartered in Chennai, IN. It trades on NYSE under ticker OLMA. Primary therapeutic focus areas include Hormone Receptor Positive Breast Carcinoma, ER+, HER2- Advanced Br

Chennai, IN HQ
2 Employees
Public company Type
OLMA · NYSE Ticker
Company details
Status
Public
HQ
Chennai, IN
Employees
2
Programs
7
Drugs
17
Patents
8
Clinical program

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Phase 1 · other · Advanced or Metastatic Solid Tumors

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors for Advanced or Metastatic Solid Tumors is a Phase 1 program (other) at Olema Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Internal code OP-3136-101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Olema Pharmaceuticals
Phase
Phase 1
Modality
other
Indication
Advanced or Metastatic Solid Tumors
Status
active
Trials
1